AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of “Moderate Buy” by Analysts

AnaptysBio, Inc. (NASDAQ:ANAB) has been given a consensus rating of “Moderate Buy” by the eleven analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $73.4444.

Several research firms have recently weighed in on ANAB. Wedbush restated an “outperform” rating and set a $50.00 price target on shares of AnaptysBio in a report on Monday, November 24th. Truist Financial set a $50.00 target price on shares of AnaptysBio in a report on Friday. HC Wainwright upped their price target on shares of AnaptysBio from $51.00 to $66.00 and gave the company a “buy” rating in a research report on Wednesday. Barclays lifted their price target on shares of AnaptysBio from $78.00 to $79.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, January 21st.

AnaptysBio News Roundup

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Stifel Nicolaus raised its price target sharply to $85 and kept a buy rating — a sizable upside vs. recent levels that likely boosted investor demand. Stifel raises PT to $85
• Positive Sentiment: Coverage noting a profitability turnaround and continued progress collecting Jemperli royalties supports a higher valuation narrative for ANAB. This fundamental story likely underpins recent buying interest. Assessing AnaptysBio valuation after profitability turnaround
• Positive Sentiment: ANAB hit a new 12‑month high following analyst upgrades, which can attract momentum and technical buying. ANAB hits new 12‑month high on analyst upgrade
• Negative Sentiment: HC Wainwright issued a mixed set of estimate changes: it lowered near‑term FY2026 and Q1/Q2 EPS forecasts (worse near‑term profitability) even as it raised several multi‑year estimates; the negative near‑term revisions could pressure sentiment despite the firm’s buy rating and $66 target. HC Wainwright estimate changes (MarketBeat summary)
• Neutral Sentiment: Short‑interest entries in recent reports are inconsistent/zero (showing NaN increases), indicating unreliable short‑interest data — not a clear driver of today’s move. (No reliable link provided in the filings.)

Insider Buying and Selling

In related news, CEO Daniel Faga sold 15,309 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $43.26, for a total value of $662,267.34. Following the sale, the chief executive officer directly owned 458,139 shares in the company, valued at $19,819,093.14. This represents a 3.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Dennis Mulroy sold 15,725 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $44.85, for a total transaction of $705,266.25. Following the sale, the chief financial officer directly owned 9,401 shares of the company’s stock, valued at $421,634.85. This represents a 62.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 156,280 shares of company stock valued at $7,254,939 over the last three months. 33.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of AnaptysBio by 4.5% during the 4th quarter. Vanguard Group Inc. now owns 1,544,037 shares of the biotechnology company’s stock worth $74,855,000 after purchasing an additional 67,048 shares in the last quarter. State Street Corp increased its position in AnaptysBio by 20.6% in the 4th quarter. State Street Corp now owns 1,053,474 shares of the biotechnology company’s stock valued at $51,072,000 after buying an additional 180,042 shares in the last quarter. Assenagon Asset Management S.A. increased its position in AnaptysBio by 4,852.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock valued at $25,719,000 after buying an additional 822,975 shares in the last quarter. 683 Capital Management LLC raised its stake in AnaptysBio by 18.5% during the 4th quarter. 683 Capital Management LLC now owns 648,093 shares of the biotechnology company’s stock worth $31,420,000 after buying an additional 101,093 shares during the period. Finally, Affinity Asset Advisors LLC acquired a new position in AnaptysBio during the 4th quarter worth approximately $21,559,000.

AnaptysBio Stock Down 3.3%

NASDAQ ANAB opened at $55.41 on Friday. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -106.56 and a beta of 0.32. AnaptysBio has a twelve month low of $15.32 and a twelve month high of $63.47. The business’s fifty day moving average is $50.27 and its 200 day moving average is $39.03.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Monday, March 9th. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.69. The business had revenue of $108.25 million during the quarter, compared to analysts’ expectations of $87.09 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%. On average, research analysts anticipate that AnaptysBio will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its Board of Directors has authorized a stock repurchase plan on Friday, November 21st that authorizes the company to repurchase $100.00 million in shares. This repurchase authorization authorizes the biotechnology company to buy up to 9.6% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.